Detalles de la búsqueda
1.
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
Lancet
; 399(10328): 909-923, 2022 03 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35248186
2.
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough.
Ann Allergy Asthma Immunol
; 130(1): 60-66, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35569802
3.
Validation and Meaningful Change Thresholds for an Objective Cough Frequency Measurement in Chronic Cough.
Lung
; 200(6): 717-724, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36348054
4.
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
Lung
; 200(4): 423-429, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35895098
5.
A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
Allergol Int
; 71(4): 498-504, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35752582
6.
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
Lung
; 199(2): 121-129, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33825965
7.
Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
Pulm Pharmacol Ther
; 56: 75-78, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30880151
8.
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks.
Am J Respir Crit Care Med
; 207(11): 1539-1542, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36996347
9.
Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough.
Ther Adv Respir Dis
; 16: 17534666221099737, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35614875
10.
Validation of a visual analog scale for assessing cough severity in patients with chronic cough.
Ther Adv Respir Dis
; 15: 17534666211049743, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34697975
11.
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
ERJ Open Res
; 6(4)2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33263037
12.
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Lancet Respir Med
; 8(8): 775-785, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32109425
Resultados
1 -
12
de 12
1
Próxima >
>>